IL17A and psoriasis: Our purpose was to elucidate the real-world incidences of adverse events of interest, including new-onset IBD, oral/GI candidiasis, pulmonary tuberculosis, herpes zoster, and major cardiovascular events (MACEs) in patients with psoriasis treated using TNF-α, IL-12/23, IL-17, and IL-23 inhibitors.